BDRX (Biodexa Pharmaceuticals) Insider Ownership: 0.02 % (As of Sep. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDRX Biodexa Pharmaceuticals PLC BDRX
24 GF Score
Price $0.81
GF Value $0.70
! 1 Warning Sign
View Full Analysis

What is Biodexa Pharmaceuticals Insider Ownership?

Biodexa Pharmaceuticals BDRX -6.50% 24 Insider Ownership is 0.02 % as of Sep. 01, 2026. GuruFocus rates BDRX with a GF Score™ of 24/100 and a GF Value™ of $0.70. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biodexa Pharmaceuticals's insider ownership is 0.02%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biodexa Pharmaceuticals's Institutional Ownership is 1.83%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biodexa Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.91%.

Biodexa Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Insider Ownership Chart

Biodexa Pharmaceuticals Historical Data

The historical data trend for Biodexa Pharmaceuticals can be seen below:

2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31 2025-06-30 2025-07-31
Insider Ownership 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
BDRX
24GF Score
Biodexa Pharmaceuticals PLC BDRX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.02 % mean?
Biodexa Pharmaceuticals (BDRX) has a Insider Ownership of 0.02 % as of Sep. 01, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Insider Ownership too high?
Biodexa Pharmaceuticals' current Insider Ownership is 0.02 %. Overall, Biodexa Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Insider Ownership compare to ZVSA and AGTX?
Biodexa Pharmaceuticals' Insider Ownership of 0.02 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Insider Ownership is 0.02 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (BDRX) has a current Insider Ownership of 0.02 %. The stock's GF Value™ is $0.70, compared to a current price of $0.81 — trading 15.6% above its estimated fair value. The current Insider Ownership is 0.02 %. Biodexa Pharmaceuticals' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Insider Ownership is 0.02 % as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $0.81 is trading 15.6% above its estimated GF Value™ of $0.70.

Key valuation signals for BDRX:

  • Insider Ownership: 0.02 %
  • GF Value™: $0.70 vs. price of $0.81 (15.6% above fair value)
  • GF Score™: 24/100 with 1 warning sign

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
24GF Score

Get the complete analysis for BDRX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price
$0.70
GF Value